Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous work demonstrated that phosphorylation of Y105-PKM2 by NPM-ALK regulates a major metabolic shift to promote lymphomagenesis.
|
28414323 |
2017 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will first outline how these different cell and mouse models were designed, and what key findings they revealed (or confirmed) towards oncogenic ALK-induced lymphomagenesis.
|
25961699 |
2015 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.
|
23673339 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gene fusion product and the transcription factor STAT3 are both phosphorylated, and thereby the pathogenetic mechanism of this case shows important analogies with that of NPM-ALK and CLTC-ALK lymphomas, in which STAT3 plays a central role in the lymphomagenesis.
|
23588372 |
2013 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The dichloromethane extract of the ethnomedicinal plant Neurolaena lobata inhibits NPM/ALK expression which is causal for anaplastic large cell lymphomagenesis.
|
23135783 |
2013 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of NPM-ALK lymphomagenesis in transgenic mice showed p16INK4a-dependent accumulation of senescent cells in premalignant lesions and decreased tumor latency in the absence of p16INK4a.
|
21518927 |
2011 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report here the development of novel conditional mouse models for ALK-induced lymphomagenesis, with the use of the tetracycline regulatory system under the control of the EmuSRalpha enhancer/promoter.
|
20223922 |
2010 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To unravel the regulatory network underlying nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) -mediated lymphomagenesis of anaplastic large-cell lymphoma (ALCL) and to discover diagnostic genomic classifiers for the recognition of patients with ALK-positive and ALK-negative ALCL among T-cell non-Hodgkin's lymphoma (T-NHL).
|
20159827 |
2010 |
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the t(2;5) product nucleophosmin-ALK has been extensively studied for its transforming properties, very little is known regarding cooperative genetic mutations that may contribute to lymphomagenesis and may predict survival outcome, specifically in a purely pediatric population.
|
19691112 |
2009 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the essential role of STAT3 activation as well as STAT 5 activation in nucleophosmin-ALK fusion protein-mediated lymphomagenesis was reported.
|
18755494 |
2009 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the ALK pathways sustaining lymphomagenesis and tumor maintenance, we analyzed the tyrosine-kinase protein profiles of ALK-positive cell lines using 2 complementary proteomic-based approaches, taking advantage of a specific ALK RNA interference (RNAi) or cell-permeable inhibitors.
|
18845790 |
2009 |
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These translocations induce the ectopic expression of X-ALK proteins, thought to be involved in lymphomagenesis, through the dysregulation of cell proliferation and apoptotic pathways.
|
16900211 |
2006 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
|
15902287 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NPM-ALK chimeric protein is an activated tyrosine kinase that has been shown to be a potent oncogene and presumably plays a causative role in lymphomagenesis.
|
16101126 |
2005 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our data indicate that NPM/ALK-induced activation of STAT5 may play an important role in NPM/ALK-mediated lymphomagenesis.
|
11522649 |
2001 |
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sporadic variant 2p23/ALK abnormalities identified in ALK-positive ALCL indicate that genes other than NPM may also be involved in the deregulation of ALK and lymphomagenesis.
|
9763551 |
1998 |